Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

01-01-2008 | Pediatrics

Effect of oral CDP-choline on visual function in young amblyopic patients

Authors: Michela Fresina, Anna Dickmann, Annabella Salerni, Fabio De Gregorio, Emilio C. Campos

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 1/2008

Abstract

Purpose

The purpose of the study was to evaluate the effect on visual function of orally administered CDP-choline in addition to patching for the treatment of amblyopia in children.

Methods

This was an open label parallel group study comparing patching plus oral CDP-choline with patching alone. Sixty-one participants (aged between 5 and 10 years) suffering from anisometropic or strabismic amblyopia were divided at random into two groups: Group A, 800 or 1,200 mg (according to the body weight) of orally administered CDP-choline and 2-h patching a day; Group B, 2-h patching a day. Both groups were treated for 30 consecutive days. A follow-up visit was set 60 days after the treatment was discontinued. The main outcome measure was the change in visual acuity of amblyopic eyes as measured by Snellen’s E charts. The secondary outcome measures were changes in the visual acuity of amblyopic eye as measured by isolated letters (Snellen’s E) and changes in the contrast sensitivity of amblyopic eyes.

Results

The addition of CDP-choline to patching therapy was not found to be more effective than patching alone after 30-day treatment. The present results showed that adding CDP-choline to patching stabilised the effects obtained during the treatment period. In fact, whereas the participants treated only with patching showed a decrease in visual acuity at 90 days, these receiving CDP-choline and patching combined appeared to maintain the results obtained (two-way ANOVA: P = 0.0042). Similar results were obtained when measuring visual acuity by isolated Snellen’s E letters.

Conclusions

In amblyopic patients, CDP-choline combined with patching contributes to obtaining more stable effects than patching alone.

Snowdon SK, Stewart-Brown SL (1997) Preschool vision screening. Health Technol Assess 1:1–85

Newman DK, East MM (2000) Prevalence of amblyopia among defaulters of preschool vision screening. Ophthalmic Epidemiol 7(1):67–71PubMedCrossRef

Adams DL (2005) Normal and abnormal visual development. In: Taylor D, Hoyt CS (eds) Pediatric ophthalmology and strabismus. Elsevier Saunders, Edinburgh, pp 9–22

Repka MX (2005) Amblyopia management. In: Taylor D, Hoyt CS (eds) Pediatric ophthalmology and strabismus. Elsevier Saunders, Edinburgh, pp 862–868

Secades JJ (2001) CDP-choline update and review of its pharmacology and clinical use. Methods Find Exp Clin Pharmacol 23 [Suppl B]:1–53

Secades J, Frontera G (1995) CDP-choline: pharmacological and clinical review. Methods Find Exp Clin Pharmacol 17 [Suppl B]:1–54PubMed

Agnoli A, Ruggieri S, Denaro A, Bruno G (1982) New strategies in the management of Parkinson’s disease. A biological approach using a phospholipid precursor (CDP-choline). Neuropsychobiology 8:289–296PubMed

Eberhardt R, Birbamer G, Gerstenbrand F, Rainer E, Traegner H (1990) Citicoline in the treatment of Parkinson’s disease. Clin Ther 12:489–495PubMed

Davalos A, Castillo J, Alvarez-Sabin JA et al (2002) Oral citicoline in acute ischemic stroke. An individual patient data pooling analysis of clinical trials. Stroke 33:2850–2857PubMedCrossRef

10.

Martinez-Villa E, Sieria PI (2001) Current status and perspectives of neuroprotection in ischemic stroke treatment. Cerebrovasc Dis 11 [Suppl 1]:60–70CrossRef

11.

Pecori Giraldi J, Virno M, Covelli G, Grechi G, De Gregorio F (1989) Therapeutic value of citicoline in the treatment of glaucoma (computerized and automated perimetric investigation). Int Ophthalmol 13:109–112PubMedCrossRef

12.

Covelli GP, De Gregorio F, Grechi G, Pecori Giraldi J (1989) Efficacia della citicolina nei difetti perimetrici a settore. Boll Ocul 68 [Suppl 4]:353–361

13.

Virno M, Pecori Giraldi J, Liguori A, De Gregorio F (2000) The protective effect of citicoline on the progression of the perimetric defects in glaucomatous patients (perimetric study with a 10-year follow-up). Acta Ophthalmol Scand 78 [Suppl]:56–57

14.

Brogliatti B, Rolle T, Cantatore A, Bianco M (1991) Citicolina versus gangliosidi versus GM1: effetti sulla sensibilità retinica centrale in pazienti glaucomatosi. Boll Ocul 70 [Suppl 2]:1–8

15.

Parisi V, Manni G, Colacino G, Bucci MG (1999) Cytidine-5′-diphosphocholine (citicoline) improves retinal and cortical responses in patients with glaucoma. Ophthalmology 106(6):1126–1134PubMedCrossRef

16.

McMurray WC, Magee WI (1972) Phospholipid metabolism. Ann Rev Biochem 41:129–161PubMedCrossRef

17.

Farooqui AA, Horrocks LA, Farooqui T (2000) Glycerophospholipids in brain: their metabolism incorporation to membranes, function, and involvement in neurological disorders. Chem Phys Lipids 106:1–29PubMedCrossRef

18.

Cohadon F, Rigoulet M, Guerin B, Vendendriessche M (1979) Edeme cerebral vasogenique. Alterations des ATPases membranaires. Restauration par un precurseur des phospholipides. Nouv Presse Med 8:1589–1591PubMed

19.

Goto Y, Okamoto S, Yonekawa Y et al (1988) Degradation of phospholipid molecular species during experimental cerebral ischemia in rats. Stroke 19:728–735PubMed

20.

Hirashima Y, Moto A, Endo S, Takaku A (1989) Activities of enzymes metabolizing phospholipids in rat cerebral ischemia. Mol Chem Neuropathol 10:87–100PubMedCrossRef

21.

Cohen MM (1973) Biochemistry of cerebral anoxia, hypoxia and ischemia. Monogr Neural Sci 1:1–49PubMed

22.

Mykita S, Golly F, Dreyfus H, Freysz L, Massarelli R (1986) Effect of CDP-choline on hypocapnic neurons in culture. J Neurochem 47:223–231PubMedCrossRef

23.

Schäbitz WR, Weber J, Takano K, Sandage BW, Locke KW, Fisher M (1996) The effect of prolonged treatment with citicoline in temporary experimental focal ischemia. J Neurol Sci 183:21–25CrossRef

24.

Bladergroen BA, Bussiere M, Klein W et al (1999) Inhibition of phosphatidylcholine and phosphatidylethanolamine biosynthesis in rat-2 fibroblasts by cell-permeable ceramides. Eur J Biochem 264:152–160PubMedCrossRef

25.

Rao AM, Hatcher JF, Dempsey RJ (2001) Does CDP-choline modulate phospholipase activities after transient forebrain ischemia? Brain Res 893:268–272PubMedCrossRef

26.

Onal MZ, Tatlisumak T, Locke KW, Sandage BW, Fisher M (1997) Synergistic effect of citicoline and MK-801 in temporary experimental focal ischemia in rats. Stroke 28:1060–1065PubMed

27.

Agut J, Coviella IL, Wurtman RJ (1984) Cytidine(5′)diphosphocholine enhances the ability of haloperidol to increase dopamine metabolites in the striatum of the rat and to diminish stereotyped behavior induced by apomorphine. Neuropharmacology 23:1403–1406PubMedCrossRef

28.

Witkovsky P, Dearry A (1991) Functional roles of dopamine in the vertebrate retina. Prog Retin Res 11:247–292CrossRef

29.

Simon A, Nguyen-Legros J (1995) Are there dopaminergic ganglion cells in the mammalian retina? Neurochem Int 27:279–283PubMedCrossRef

30.

Nguyen-Legros J, Harnois C, DiPaolo T, Simon A (1993) The retinal dopamine system in Parkinson’s disease. Clin Vis Sci 8:1–12

31.

Gottlob I, Schneider E, Heider W, Skrandies W (1987) Alteration of visual evoked potentials and electroretinograms in Parkinson’s disease. Electroencephalogr Clin Neurophysiol 66:349–357PubMedCrossRef

32.

Antal A, Bandini F, Keri S, Bodis-Wollner I (1998) Visuo-cognitive dysfunctions in Parkinson’s disease. Clin Neurosci 5:147–152PubMed

33.

Rejdak R, Toczoowski J, Solski J, Duma D, Grieb P (2002) Citicoline treatment increases retinal dopamine content in rabbits. Ophthalmic Res 34:146–149PubMedCrossRef

34.

Gottlob I, Charlier J, Reinecke RD (1992) Visual acuities and scotomas after one week levodopa administration in human amblyopia. Invest Ophthalmol Vis Sci 33(9):2722–2728PubMed

35.

Leguire LE, Rogers GL, Wilson PD et al (1998) Occlusion and levodopa-carbidopa treatment for childhood amblyopia. J AAPOS 2:257–264PubMedCrossRef

36.

Campos EC, Bolzani R, Schiavi C, Baldi A, Porciatti V (1997) Cytidin-5′-diphosphocholine enhances the effect of part-time occlusion in amblyopia. Doc Ophthalmol 93:247–263CrossRef

37.

Campos EC, Schiavi C, Benedetti P, Bolzani R, Porciatti V (1995) Effect of citicoline on visual acuity in amblyopia: preliminary results. Graefes Arch Clin Exp Ophthalmol 233:307–312PubMed

38.

Campos EC (1997) Future direction in the treatment of amblyopia. Lancet 349:1190PubMedCrossRef

39.

Porciatti V, Schiavi C, Benedetti P, Baldi A, Campos EC (1998) Cytidine-5′-diphosphocholine improves visual acuity, contrast sensitivity and visual-evoked potentials of amblyopic subjects. Curr Eye Res 17:141–148PubMedCrossRef

40.

Becker R, Graf M (2006) Landolt C and Snellen E acuity: differences in strabismus amblyopia? Klin Monatsbl Augenheilkd 223:24–28PubMedCrossRef

41.

Galletti P, De Rosa M, Nappi MA, Pontoni G, Del Piano L, Salluzzo A, Zappia V (1985) Transport and metabolism of double-labelled CDP-choline in mammalian tissues. Biochem Pharmacol 34:4121–4130PubMedCrossRef

42.

Lopez-Coviella I, Agut J, Savci V, Ortiz JA, Wurtman RJ (1995) Evidence that 5′-cytidinediphosphocholine can affect brain phospholipid composition by increasing choline and cytidine plasma level. J Neurochem 65:889–894PubMedCrossRef

43.

Agut J, Font E, Sacristan A, Ortiz JA (1983) Bioavailability of methyl¹⁴C CDP-choline by oral route. Arzneimittelforschung 33(II):1045–1047PubMed

44.

Lopez-Coviella I, Agut J, Von Borstel R, Wurtman RJ (1987) Metabolism of cytidine (5′)-diphosphocholine (CDP-choline) following oral and intravenous administration to the human and the rat. Neurochem Int 11:293–297CrossRef

45.

Grau T, Romero A, Sacristan A, Ortiz JA (1983) CDP-choline: acute toxicity study. Arzneimittelforschung 33(II):1033–1034PubMed

46.

Grau T, Romero A, Sacristan A, Ortiz JA (1983) Study of subacute toxicity of CDP-choline after 30 days of oral administration. Arzneimittelforschung 33(II):1035–1038PubMed

47.

Grau T, Romero A, Sacristan A, Ortiz JA (1983) CDP-choline: 6-month study toxicity on dogs. Arzneimittelforschung 33(II):1038–1042PubMed

Title: Effect of oral CDP-choline on visual function in young amblyopic patients
Authors: Michela Fresina
Anna Dickmann
Annabella Salerni
Fabio De Gregorio
Emilio C. Campos
Publication date: 01-01-2008
Publisher: Springer-Verlag
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 1/2008
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-007-0621-6

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Effect of oral CDP-choline on visual function in young amblyopic patients

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2008

The prevalence of retinal angiomatous proliferation in age-related macular degeneration with occult choroidal neovascularization

An association between vascular endothelial growth factor gene promoter polymorphisms and diabetic retinopathy

Combined intravitreal bevacizumab and photodynamic therapy for neovascular age-related macular degeneration

Spontaneous closure of stage III and IV idiopathic full-thickness macular holes—a two-case report

Ocular fundus auto-fluorescence observations at different wavelengths in patients with age-related macular degeneration and diabetic retinopathy

Topical treatment with nerve growth factor in an animal model of herpetic keratitis